CYTOKINETICS, INCORPORATED Proceeds and Excess Tax Benefit from Share-based Compensation
CYTOKINETICS, INCORPORATED (CYTK) had Proceeds and Excess Tax Benefit from Share-based Compensation of $700.00 thousand as of 2018-01-01, per its 10-K filed 2018-03-05.
Discontinued › Notes › Compensation Related Costs
us-gaap:ProceedsAndExcessTaxBenefitFromSharebasedCompensation · last filed 2018-03-05
- 2018-01-01: Proceeds and Excess Tax Benefit from Share-based Compensation $700.00K.
- 2017-01-01: Proceeds and Excess Tax Benefit from Share-based Compensation $700.00K.
| Period end | Proceeds and Excess Tax Benefit from Share-based Compensation |
|---|---|
| 2018-01-01 | $700.00K 10-K · filed 2018-03-05 |
| 2017-01-01 | $700.00K 10-Q · filed 2017-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |